Evidence map›Paper›PMID 32295255›Full record

ArticlePharmaceutics2020

Characterization and Mathematical Modeling of Alginate/Chitosan-Based Nanoparticles Releasing the Chemokine CXCL12 to Attract Glioblastoma Cells.

Suzanne Gascon, Angéla Giraldo Solano, Wiam El Kheir, Hélène Therriault, Pierre Berthelin, Bettina Cattier, Bernard Marcos, Nick Virgilio, Benoit Paquette, Nathalie Faucheux and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Suzanne GasconLaboratory of Cell-Biomaterial Biohybrid Systems, Department of Chemical and Biotechnological Engineering, Faculty of Engineering, Université de Sherbrooke, 2500 boul universite, Sherbrooke, QC J1K 2R1, Canada.
Angéla Giraldo SolanoDepartment of nuclear medicine and radiobiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 12e avenue Nord, Sherbrooke, QC J1H 5N4, Canada.ORCID 0000-0001-8984-1348
Wiam El KheirAdvanced dynamic cell culture systems laboratory, Department of Chemical and Biotechnology Engineering, Faculty of Engineering, Université de Sherbrooke, 2500 boul universite, Sherbrooke, QC J1K 2R1, Canada.
Hélène TherriaultDepartment of nuclear medicine and radiobiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 12e avenue Nord, Sherbrooke, QC J1H 5N4, Canada.
Pierre BerthelinLaboratory of Cell-Biomaterial Biohybrid Systems, Department of Chemical and Biotechnological Engineering, Faculty of Engineering, Université de Sherbrooke, 2500 boul universite, Sherbrooke, QC J1K 2R1, Canada.
Bettina CattierAdvanced dynamic cell culture systems laboratory, Department of Chemical and Biotechnology Engineering, Faculty of Engineering, Université de Sherbrooke, 2500 boul universite, Sherbrooke, QC J1K 2R1, Canada.
Bernard MarcosDepartment of Chemical and Biotechnology Engineering, Faculty of Engineering, Université de Sherbrooke, 2500 boul universite, Sherbrooke, QC J1K 2R1, Canada.
Nick VirgilioDepartment of chemical engineering, Polytechnique Montréal, Montréal, QC H3C 3A7, Canada.
Benoit PaquetteDepartment of nuclear medicine and radiobiology, Faculty of Medicine and Health Science, Université de Sherbrooke, 12e avenue Nord, Sherbrooke, QC J1H 5N4, Canada.ORCID 0000-0002-2117-8372
Nathalie FaucheuxLaboratory of Cell-Biomaterial Biohybrid Systems, Department of Chemical and Biotechnological Engineering, Faculty of Engineering, Université de Sherbrooke, 2500 boul universite, Sherbrooke, QC J1K 2R1, Canada.
Marc-Antoine LauzonAdvanced dynamic cell culture systems laboratory, Department of Chemical and Biotechnology Engineering, Faculty of Engineering, Université de Sherbrooke, 2500 boul universite, Sherbrooke, QC J1K 2R1, Canada.
Université de Sherbrooke · CAPolytechnique Montréal · CA

Funding

New Frontiers in Research Fund - Exploration NFRFE-2018-00764
6 · The paper itself

Abstract

Chitosan (Chit) currently used to prepare nanoparticles (NPs) for brain application can be complexed with negatively charged polymers such as alginate (Alg) to better entrap positively charged molecules such as CXCL12. A sustained CXCL12 gradient created by a delivery system can be used, as a therapeutic approach, to control the migration of cancerous cells infiltrated in peri-tumoral tissues similar to those of glioblastoma multiforme (GBM). For this purpose, we prepared Alg/Chit NPs entrapping CXCL12 and characterized them. We demonstrated that Alg/Chit NPs, with an average size of ~250 nm, entrapped CXCL12 with ~98% efficiency for initial mass loadings varying from 0.372 to 1.490 µg/mg NPs. The release kinetic profiles of CXCL12 were dependent on the initial mass loading, and the released chemokine from NPs after seven days reached 12.6%, 32.3%, and 59.9% of cumulative release for initial contents of 0.372, 0.744, and 1.490 µg CXCL12/mg NPs, respectively. Mathematical modeling of released kinetics showed a predominant diffusive process with strong interactions between Alg and CXCL12. The CXCL12-NPs were not toxic and did not promote F98 GBM cell proliferation, while the released CXCL12 kept its chemotaxis effect. Thus, we developed an efficient and tunable CXCL12 delivery system as a promising therapeutic strategy that aims to be injected into a hydrogel used to fill the cavity after surgical tumor resection. This system will be used to attract infiltrated GBM cells prior to their elimination by conventional treatment without affecting a large zone of healthy brain tissue.

Indexed as

alginatecell migrationchemokinechitosandelivery systemmathematical modelingnanoparticles

Identifiers

PMID32295255
PMCPMC7238026
OpenAlexW3016569486

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.